1. Medtech Insight
  2. >>Business

Q&A With Nadim Yared: AdvaMed's Next Chair On Capital Formation And Global Challenges

 
• By David Filmore

Nadim Yared is set to become the first small-company CEO ever to chair AdvaMed's board of directors in March. The CVRx executive spoke to Medtech Insight about what that means, the challenge of raising funds in medtech, and AdvaMed's role in the current political environment in the US and abroad.

Yared

Nadim Yared has been fighting the good fight of a medtech startup for the past 10 years as CEO of cardiovascular neurostimulation firm CVRx Inc.More recently, he has taken on a more prominent role in policy advocacy for industry, first as chairman of AdvaMed Accel, the division of the industry trade group that is focused on emerging-growth companies. And now he has been elected as the next chairman of AdvaMed's board of directors.

When Yared takes on the board chairman role next March, it will be the first time an executive of a small company has filled a post traditionally reserved for the Medtronics, J&Js and BDs of the world. His appointment is no accident, Yared affirms

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 
• By Brian Bossetta

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

More from Medtech Insight

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 
• By Brian Bossetta

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.